Actualités

Net loss improved 5% on international partnerships and manufacturing gains.

MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.

Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt

Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.

President Donald Trump discussed efforts to de-escalate US-Iran tensions with Qatari Emir Tamim bin Hamad Al Thani.

The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.

Moby summary of Moderna, Inc.'s Q2 2026 earnings call

Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.

Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.

The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower

Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha

Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.

Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 million. Its GAAP loss of $1.97 per share was 4.2% above analysts’ consensus estimates.

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know.

Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at therapeutics stocks, starting with Moderna (NASDAQ:MRNA).

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.

Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.

Moderna (MRNA) drew fresh attention after appointing experienced financial executive Michael McDonnell to its Board and Audit Committee, as the stock recently declined 3.77% and an earnings report is scheduled for July 31, 2026. See our latest analysis for Moderna. Moderna shares have been volatile, with the 7-day share price return down 11.54% and the 30-day share price return down 6.72%. However, the year to date share price return of 93.32% and 1-year total shareholder return of 82.28%...

The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Most Profitable Small Cap Stocks to Buy. On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna. The company said revenue jumped from $1.8 million a year earlier because of […]

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Earnings season is winding down, but we still have a couple of big name companies reporting. This week we have Broadcom, Crowdstrike, Palo Alto Networks, Medtronic and Ciena Corp all reporting.

Roivant Sciences Ltd (ROIV) strengthens its financial position with a $2.25 billion Moderna settlement and prepares for key drug launches amidst mixed study results.